NuCana (NCNA) Net Income towards Common Stockholders (2017 - 2025)

NuCana's (NCNA) quarterly Net Income towards Common Stockholders came in at -$3.5 million in Q4 2025, down 244.62% year-on-year from $2.4 million in Q4 2024, and down 313.68% quarter-over-quarter from -$844700.7 in Q3 2025.

NuCana (NCNA) Net Income towards Common Stockholders (2017 - 2025) Analysis & Trends

NuCana has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$3.5 million for Q4 2025.

  • Net Income towards Common Stockholders for Q4 2025 came in at -$3.5 million, down 244.62% year-over-year; the trailing twelve-month figure through Dec 2025 was -$40.5 million (down 41.62% YoY), and the FY2025 annual result was -$38.7 million, down 59.38% from the prior year.
  • Net Income towards Common Stockholders came in at -$3.5 million for Q4 2025 at NuCana, down from -$844700.7 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$844700.7 in Q3 2025 to a low of -$32.6 million in Q2 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$10.4 million (2024), against an average of -$11.1 million.
  • Across the five-year window, Net Income towards Common Stockholders surged 90.89% in 2024 and sank 244.62% in 2025, its largest moves.
  • NuCana's Net Income towards Common Stockholders stood at -$21.2 million in 2021, then climbed by 6.1% to -$19.9 million in 2022, then surged by 44.03% to -$11.1 million in 2023, then soared by 90.89% to -$1.0 million in 2024, then tumbled by 244.62% to -$3.5 million in 2025.
  • The last three Net Income towards Common Stockholders figures came in at -$3.5 million (Q4 2025), -$844700.7 (Q3 2025), and -$32.6 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - -
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - -26.94 Mn
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - -13.56 Mn
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 2.50 Mn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - -14.46 Mn
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -3.63 Mn
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn 1.03 Bn
9 Abivax 94.26 Bn 94.26 Bn - -56.48 Mn
10 NuCana 29.13 Bn 29.13 Bn - -3.49 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -3.49 Mn
Sep 30, 2025 -844,700.70
Jun 30, 2025 -32.61 Mn
Mar 31, 2025 -3.56 Mn
Dec 31, 2024 -1.01 Mn
Sep 30, 2024 -6.82 Mn
Jun 30, 2024 -10.43 Mn
Mar 31, 2024 -10.33 Mn
Dec 31, 2023 -11.13 Mn
Sep 30, 2023 -10.26 Mn
Jun 30, 2023 -7.63 Mn
Mar 31, 2023 -10.77 Mn
Dec 31, 2022 -19.89 Mn
Sep 30, 2022 -7.04 Mn
Jun 30, 2022 -6.40 Mn
Mar 31, 2022 -14.00 Mn
Dec 31, 2021 -21.18 Mn
Sep 30, 2021 -13.72 Mn
Jun 30, 2021 -14.92 Mn
Mar 31, 2021 -15.81 Mn